Harnessing Immune Checkpoint Inhibitors Against Gastric Cancer: Charting the Course to Expanded Therapeutic Benefit. Biomedical Research and Therapy, [S. l.], v. 11, n. 4, p. 6305–6325, 2024. DOI: 10.15419/bmrat.v11i4.877. Disponível em: https://preservation.bmrat.org/index.php/BMRAT/article/view/877.. Acesso em: 15 nov. 2024.